MKS Inc. to Sell Its Ophir® Optics Business to TTM Technologies, Inc.

MKS agreed to sell its Ophir Optics business to TTM Technologies for $650 million in an all-cash transaction, subject to customary closing adjustments. The purchase price represents an estimated multiple of more than 18x Ophir Optics' projected FY 2026 Adjusted EBITDA.

Analysis

The asymmetry favors the seller initially: MKSI is monetizing a business at a rich stated multiple, while TTMI must demonstrate that growth or synergies justify that entry price. For MKSI, the key second-order question is not the headline proceeds but their use—debt reduction, reinvestment, or shareholder returns will determine whether the sale improves equity value or simply shrinks earnings. The market also needs Ophir’s revenue and EBITDA contribution to assess the earnings left behind; without those figures, the transaction cannot be called accretive to MKSI on a per-share basis.

For TTMI, the strategic upside depends on whether Ophir’s optics capabilities complement existing customer relationships and can be integrated without disrupting service or margins. The >18x projected FY26 adjusted EBITDA multiple raises execution risk: standalone growth, realized synergies, and any financing cost must carry the return case. The multiple is a seller’s reference point, not evidence of value creation for the buyer.

Near term, expect the relative reaction to hinge on purchase-price adjustments, closing conditions, and MKSI’s stated capital-allocation plan. Over 1–3 months, track close timing, financing, and updated guidance; over 6–18 months, test whether TTMI grows Ophir’s earnings and whether MKSI deploys proceeds above its cost of capital. The contrarian angle: investors may treat a premium sale as automatically positive for MKSI and overlook earnings surrendered, while underweighting the execution burden on TTMI. No high-conviction outright trade without segment contribution and proceeds-use details.

Key Decisions for Investors

• Relative-value bias: prefer MKSI over TTMI on weakness around the announcement, but size modestly until MKSI discloses Ophir’s contribution to earnings and its intended use of proceeds. The thesis weakens if MKSI retains cash without a credible return plan or guidance implies a material earnings hole.
• For TTMI, avoid treating the transaction as immediately accretive. Reassess after financing terms and integration targets are disclosed; monitor acquired-business revenue/EBITDA and any change in TTMI’s leverage or margin outlook. Failure to show a credible path to returns commensurate with the purchase multiple is a reason to reduce exposure.
• Catalyst watch: verify customary closing adjustments, regulatory/closing conditions, and the expected close date. A delay, lower final proceeds, or adverse financing terms would undermine the near-term seller-positive view.
• Before placing a directional trade, obtain Ophir’s trailing and projected EBITDA, MKSI’s post-sale pro forma earnings and balance-sheet figures, and TTMI’s funding plan. If these are not provided, treat the event as a watch item rather than an earnings estimate.